Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Propanc Biopharma, Inc. issued 100 shares of Series C Preferred Stock of preferred stock to Hexstone Capital LLC for cash payment of $1,000,099.00.
- Security
- preferred stock
- Shares
- 100 shares of Series C Preferred Stock
- Purchaser
- Hexstone Capital LLC
- Consideration
- cash payment of $1,000,099.00
Exact text from the filing
Hexstone purchased 100 shares of Series C Preferred Stock of the Company and a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock, at an exercise price of $10,000 per Warrant share in exchange for cash payment of $1,000,099.00 to the Company.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Propanc Biopharma, Inc. issued up to an additional 9,900 shares of Series C Preferred Stock of warrant to Hexstone Capital LLC for cash payment of $1,000,099.00.
- Security
- warrant
- Shares
- up to an additional 9,900 shares of Series C Preferred Stock
- Purchaser
- Hexstone Capital LLC
- Consideration
- cash payment of $1,000,099.00
Exact text from the filing
a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock, at an exercise price of $10,000 per Warrant share in exchange for cash payment of $1,000,099.00 to the Company.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Propanc Biopharma, Inc.: Filed Certificate of Designation creating Series C Preferred Stock as an amendment to the Certificate of Incorporation (effective 2025-11-04).
- Change
- charter amendment
- Effective
- 2025-11-04
Exact text from the filing
On November 4, 2025, the Company amended its Certificate of Incorporation and filed a Certificate of Designation with the Delaware Secretary of State that authorized the issuance of up to 9,900 shares of a new series of preferred stock, par value $0.01 per share, designated as “Series C Preferred Stock” for which the Board established the rights, preferences and limitations thereof.
View on SEC.gov